Ambu (BATS-CHIXE:AMBUBC) - Stock Price, News & Analysis

AMBUBC Stock Overview

Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide.

AMBUBC fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	4/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings are forecast to grow 29.56% per year

Earnings grew by 150.5% over the past year

Risk Analysis

Shares are highly illiquid

Ambu A/S Competitors

Smith & Nephew

LSE:SN.

UK£8.6b

EKF Diagnostics Holdings

AIM:EKF

UK£125.2m

ConvaTec Group

LSE:CTEC

UK£5.3b

Mediclinic International

LSE:MDC

UK£3.7b

Price History & Performance

Summary of all time highs, changes and price drops for Ambu
Historical stock prices
Current Share Price	kr.110.25
52 Week High	kr.121.90
52 Week Low	kr.89.02
Beta	0.87
1 Month Change	-1.93%
3 Month Change	-5.00%
1 Year Change	2.13%
3 Year Change	-68.40%
5 Year Change	-38.81%
Change since IPO	761.33%

Recent updates

Shareholder Returns

	AMBUBC	GB Medical Equipment	GB Market
7D	-2.8%	-2.0%	2.8%
1Y	2.1%	-13.9%	1.1%

Return vs Industry: AMBUBC exceeded the UK Medical Equipment industry which returned -13.9% over the past year.

Return vs Market: AMBUBC exceeded the UK Market which returned 1.1% over the past year.

Price Volatility

Is AMBUBC's price volatile compared to industry and market?
AMBUBC volatility
AMBUBC Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	8.2%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.3%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: AMBUBC has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine AMBUBC's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1937	4,600	Britt Jensen	www.ambu.com

Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, cystoscopes, and display units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products.

Ambu A/S Fundamentals Summary

How do Ambu's earnings and revenue compare to its market cap?
AMBUBC fundamental statistics
Market cap	kr.29.44b
Earnings (TTM)	kr.238.00m
Revenue (TTM)	kr.4.90b

123.7x

P/E Ratio

6.0x

P/S Ratio

Is AMBUBC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AMBUBC income statement (TTM)
Revenue	kr.4.90b
Cost of Revenue	kr.2.11b
Gross Profit	kr.2.79b
Other Expenses	kr.2.55b
Earnings	kr.238.00m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 14, 2024

Earnings per share (EPS)	0.89
Gross Margin	56.97%
Net Profit Margin	4.86%
Debt/Equity Ratio	0%

How did AMBUBC perform over the long term?

See historical performance and comparison

AMBUBC Stock Overview

Rewards

Risk Analysis

Ambu A/S Competitors

LSE:SN.

UK£8.6b

AIM:EKF

UK£125.2m

LSE:CTEC

UK£5.3b

LSE:MDC

UK£3.7b

Price History & Performance

Recent News & Updates

First quarter 2024 earnings released: EPS: kr.0.35 (vs kr.0.09 in 1Q 2023)

Ambu A/S Maintains Earnings Guidance for the Full-Year 2023/24

Ambu A/S Elects Shacey Petrovic as Vice Chair of Board of Directors

High number of new directors

Ambu A/S Announces Henrik Ehlers Wulff Not to Run for Re-Election for Board of Directors

Ambu A/S Provides Earnings Guidance for the Full-Year 2023/24

Recent updates

First quarter 2024 earnings released: EPS: kr.0.35 (vs kr.0.09 in 1Q 2023)

Ambu A/S Maintains Earnings Guidance for the Full-Year 2023/24

Ambu A/S Elects Shacey Petrovic as Vice Chair of Board of Directors

High number of new directors

Ambu A/S Announces Henrik Ehlers Wulff Not to Run for Re-Election for Board of Directors

Ambu A/S Provides Earnings Guidance for the Full-Year 2023/24

Ambu A/S Appoints Henrik Skak Bender as Member of the Executive Management, Effective 1 January 2024

Ambu A/S Announces Chief Financial Officer Changes

Ambu A/S to Report Q2, 2024 Results on May 14, 2024

Ambu A/S Narrows Earnings Guidance for the Full-Year 2022/23

Third quarter 2023 earnings released

High number of new directors

Ambu A/S Raises Earnings Guidance for the Full-Year 2022/2023

Ambu A/S Raises Earnings Guidance for the Full-Year 2022/2023

High number of new directors

Second quarter 2023 earnings released

High number of new directors

High number of new directors

First quarter 2023 earnings released: EPS: kr.0.09 (vs kr.0.08 in 1Q 2022)

High number of new directors

Ambu A/S Provides Earnings Guidance for the Financial Year of 2022-2023

High number of new directors

High number of new directors

Ambu A/S Provides Earnings Guidance for the Financial Year of 2022-2023

Full year 2022 earnings released

Ambu A/S to Report Q3, 2023 Results on Aug 31, 2023

Less than half of directors are independent

Ambu A/S(CPSE:AMBU B) dropped from FTSE All-World Index (USD)

Less than half of directors are independent

Ambu A/S Reaffirms Earnings Guidance for the Full-Year 2021/2022

Ambu A/S Revises Earnings Guidance for the Full-Year 2021/2022

Ambu Announces FDA Clearance of Fifth-Generation Single-Use Bronchoscope

Less than half of directors are independent

Ambu A/S Reaffirms Earnings Guidance for the Fiscal Year 2021/22

Second quarter 2022 earnings released

Less than half of directors are independent

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Ambu A/S Revises Revenue Guidance for the Fiscal 2022

Ambu Announces FDA Clearance of Single-Use Gastroscope and Next-Generation Display Unit

Upcoming dividend of kr.0.29 per share

Full year 2021 earnings released: EPS kr.0.98 (vs kr.0.98 in FY 2020)

Third quarter 2021 earnings released

Less than half of directors are independent

Ambu A/S Revises Revenue Guidance for the Fiscal 2021

Second quarter 2021 earnings released

Ambu A/S Reaffirms Earnings Guidance for the Fiscal Year 2021

New 90-day high: kr.331

Ambu A/S has completed a Follow-on Equity Offering in the amount of DKK 1.2345 billion.

Revenue beats expectations

New 90-day high: kr.310

First quarter 2021 earnings released

Ambu A/S to Report Fiscal Year 2021 Results on Nov 09, 2021

New 90-day high: kr.263

New 90-day high: kr.212

Upcoming Dividend of kr.0.29 Per Share

Ambu A/S Announces Board Changes

Ambu A/S to Report Q2, 2021 Results on May 12, 2021

Shareholder Returns

Price Volatility